Figure 3
From: CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
CD47ASO treatment reduced hepatic steatosis in diet-induced obese mice. (A) Representative H&E staining and Oil red O staining of liver sections from control ASO or CD47 ASO treated mice; (B) Liver triglyceride levels; (C) Liver gene expression by qPCR; (D) Plasma ALT and AST levels. Data are represented as mean ± SE (n = 4–7 mice/group). *P < 0.05, **P < 0.01, ***P < 0.001.
